

Fig.1

gene	polymorphism	gene	polymorphism
Angiotensin converting enzyme	I/D in intron 16	Insulin receptor substrate-1	3494G→A (Gly972Arg)
Angiotensin II type I receptor	-535C→T	Interleukin-10	-1082G→A
Angiotensinogen	-6G→A		-819T→C
Apolipoprotein A1	-75G→A		-592A→C
	83C→T	Interleukin-1α	-889C→T
Apolipoprotein B	I/D in signal peptide	Interleukin-1β	-511C→T
Apolipoprotein C-III	-482C→T		3953C→T
	1100C→T	Interleukin-6	-634C→G
Apolipoprotein E	-491A→T		-174G→C
	-219G→T	LDL receptor related protein	766C→T
	3932T→C (Cys112Arg)		-1887C→A
	4070C→T (Arg158Cys)	Leptin	280G→A (Asp9Asn)
	93C→T	Lipoprotein lipase	1127A→G (Asn291Ser)
Apolipoprotein (a)	121G→A	Manganese superoxide dismutase	47C→T (Ala16Val)
	11764A→C (Thr12Pro)		173T→C (Ile58Thr)
	-477C→T	Matrix Gla protein	-7G→A
ATP-binding cassette transporter 1	1051G→A (Arg219Lys)		7158A→G (Thr83Ala)
	664G→A (Val7Met)	Metalloproteinase-1 (collagenase)	-1607G→GG
	-55A→C	Metalloproteinase-12 (macrophage elastase)	-82A→G
Atrial natriuretic peptide	46A→G (Arg16Gly)	Methionine synthase	2756A→G (Asp919Gly)
Atrial natriuretic peptide clearance receptor	79C→G (Gln27Glu)	Methylene tetrahydrofolate reductase	677C→T (Ala222Val)
β2-adrenergic receptor	491C→T (Thr164Ile)	Monocyte chemoattractant protein-1	-2518G→A
	190T→C (Trp64Arg)	NADH/NADPH oxidase p22 phox	242C→T (His72Tyr)
β3-adrenergic receptor	-854G→A	Neuropeptide Y	1128T→C (Leu7Pro)
β-Fibrinogen	-455G→A	Paraoxonase	-107T→C
	148C→T		172A→T (Met55Leu)
	8059G→A (Arg448Lys)		584G→A (Gln192Arg)
CD14 receptor	-260C→T	PECAM1 (CD31)	1454C→G (Leu125Val)

Fig.2

Chemokine receptor 2	190G→A (Val64Ile)	PECAM1 (CD31)	4428G→A (Ser563Asn)
Cholesterol ester transfer protein	1061A→G (Ile405Val)	Peroxisome proliferator-activated receptor- $\alpha$	696C→G (Leu162Val)
	1163A→G (Asp442Gly)	Peroxisome proliferator-activated receptor- $\gamma$ 2	34C→G (Pro12Ala)
	1200G→A (Arg451Gln)		344C→A (Pro115Gln)
Coagulation factor V	1691G→A (Arg506Gln)	Plasminogen-activator inhibitor-1	-668/4G→5G
Coagulation factor VII	11496G→A (Arg353Glu)	Platelet-activating factor acetylhydrolase	994G→T (Val279Phe)
Coagulation factor XII	46C→T	Prothrombin	20210G→A
Coagulation factor XIII A-subunit	163G→T (Val134Leu)	P-selectin	76666A→C (Thr715Pro)
Connexin 37	1019C→T (Pro319Ser)	Scavenger receptor-BI	4G→A (Gly2Ser)
Endothelial nitric oxide synthase	-786T→C		403G→A (Val135Ile)
Endothelin-1	894G→T (Glu298Asp)	Serotonin 2A receptor	102T→C
E-selectin	5665G→T (Lys198Asn)	Stromelysin-1	-1171/5A→6A
	98G→T	Thrombomodulin	-33G→A
	561A→C (Ser128Arg)		-10GG→TA
	1839C→T (Leu554Phe)		845G→A (Ala257Thr)
Extracellular superoxide dismutase	5775C→G (Arg213Gly)	Thrombopoietin	2136C→T (Ala455Val)
Fatty acid-binding protein 2	2445G→A (Ala54Thr)	Thrombospondin 1	5713A→G
Fractalkine receptor	84635G→A (Val249Ile)	Thrombospondin 4	2210A→G (Asn700Ser)
Glycoprotein Ia	807C→T	Tissue factor pathway inhibitor	1186G→C (Ala387Pro)
	873G→A	Transforming growth factor- $\beta$ 1	874G→A (Val264Met)
	1648A→G (Lys505Glu)		-509C→T
	1018C→T (Thr145Met)		869T→C (Leu10Pro)
Glycoprotein Ib $\alpha$	1565T→C (Leu33Pro)	Tumor necrosis factor- $\alpha$	-863C→A
Glycoprotein IIIa	97A→C (Lys121Gln)		-850C→T
Glycoprotein PC-1	825C→T (splice variant)		-308G→A
G-protein $\beta$ 3 subunit	845G→A (Cys282Tyr)		-238G→A
Hemochromatosis-associated protein	-480C→T		-1234C→T
Hepatic lipase	-250G→A	von Willebrand factor	-1051G→A

Fig.3

Gene	SNP	Labels	Primers (5'→3')	Cycles	Probes (5'→3')	Formamide
Angiotensinogen	-6G→A	TxR FITC Biotin	CGGCAGCTTCTCCX <u>CG</u> GGCAGCTTCTCCX <u>TC</u> CACCCCTAGCTATAATAGG	35	AGCCACTGATGCX <u>CG</u> AGCCACTGATGCX <u>TC</u>	30%
Apolipoprotein C-III	-482C→T	Biotin FITC	CGGAGCCACTGATGC <u>CG</u> GGAGCCACTGATGC <u>TC</u> TGTGGAGTAAAGCACAGAA	35	AGCCACTGATGCX <u>TC</u>	
Apolipoprotein E	3932T→C	Biotin FITC TxR	GGACATGGAGGACGTX <u>CG</u> GGACATGGAGGACGTX <u>TC</u> CGGGTACTGCACAGGC	40		
E-selectin	561A→C	Biotin FITC	ACATTACCGTGGCCAX <u>TG</u> CATTACCGTGGCCAX <u>GG</u> AGCTGCCGTACCAATACATCC	35	CACCGTGGCCAX <u>TG</u> CACCGTGGCCAX <u>GG</u>	45%
Fatty acid-binding protein 2	2445G→A	Biotin TxR	TCACAGTCAAAGAACATCAAGX <u>GC</u> ATTACAGTCAAAGAACATCAAGX <u>AC</u> AAAAAACAAACTCAATGTTTCGA	40	GAATCAAGX <u>G</u> CTTTCGAAACATT	
G-protein β3 subunit	825C→T	Biotin FITC Biotin	TCTGGGCATCACGTX <u>CG</u> TCTGGGCATCACGTX <u>TC</u> GAATAGTAGGGCCACTGA	35	GAATCAAGX <u>A</u> CTTTTCGAAACATT	37.5%
Glycoprotein Ia	1648A→G	FITC TxR Biotin	GAGTCTACCTGTTACTATCAAX <u>AA</u> GAGTCTACCTGTTACTATCAAX <u>GA</u> ACCAGTACTAAAGCAAAATTAAACT	40		
Glycoprotein Iba	1018C→T	FITC TxR Biotin	CCCAGGGCTCCTGX <u>CG</u> CCCAGGGCTCCTGX <u>TC</u> TGAGCTTCTCCAGCTGGGTG	40		
Paraoxonase	584G→A	FITC TxR Biotin	ACCCAATAATACATCTCCAGG <u>AC</u> AACCCAAATAACATCTCCAGG <u>CT</u> GAATGATATTGTGCTGGGAC	35		
Plasminogen-activator inhibitor-1	-668/4G→5G	Biotin	GGCACAGAGAGACTCTGGACACG GGCCGCTCCGATGATAACA	35	TGGACACGTTGGGGAGTCAG TGGACACGTTGGGGAGTCAGC	45%

10/524021

**Fig.4**

Platelet-activating factor acetylhydrolase	994G→T	FITC TxR Biotin	TTCTTTGGGGAGAACXGT ATTCCTTTGGGGAGAACXGT TCTTACCTGAATCTCTGATCTCA	40
Thrombomodulin	2136C→T	FITC TxR Biotin	CCCGACTCGGCCCTTXCC CCCCGACTCGGCCCTTXTC GTCACAGTCGGTGCCTAATGT	40
Thrombopoietin	5713A→G	FITC TxR Biotin	CGGACATCAGCAATTGCTXAT CGGACATCAGCAATTGCTXGT CGGACATCAGCAATTGCTXGT	35
Thrombospondin 4	1186G→C	FITC TxR Biotin	CTGCAGGGAAAGGGAGCTGT CGAGTTGGGAACGCACT CGAGTTGGGAACGCACTXGT	35
Tumor necrosis factor- $\alpha$	-863C→A	FITC TxR Biotin	GGTCCTGCACTGACATGAG GGCCCTGTCTTCGTTAACXGG ATGGCCCTGTCTTCGTTAACXGT	35
			CCAGGGCTATGGAAAGTCGAGTATC	

Fig.5

Gene	SNP	Gene	SNP
Men		Women	
Angiotensinogen	-6G→A	Apolipoprotein C-III	-482C→T
Apolipoprotein C-III	-482C→T	Apolipoprotein E	3932T→C
Apolipoprotein C-III	1100C→T	Apolipoprotein E	4070C→T
Apolipoprotein E	-219G→T	ATP-binding cassette transporter 1	1051G→A
Apolipoprotein E	4070C→T	CD14 receptor	-260C→T
Chemokine receptor 2	190G→A	Connexin 37	1019C→T
Connexin 37	1019C→T	E-selectin	561A→C
Endothelial nitric oxide synthase	-786T→C	Endothelial nitric oxide synthase	-786T→C
G-protein β3 subunit	825C→T	Endothelin-1	5665G→T
Glycoprotein Ia	1648A→G	Fatty acid-binding protein 2	2445G→A
Interleukin-10	-819T→C	Glycoprotein Ibα	1018C→T
Interleukin-10	-592A→C	Insulin receptor substrate-1	3494G→A
NADH/NADPH oxidase p22 phox	242C→T	Interleukin-6	-634C→G
Platelet-activating factor acetylhydrolase	994G→T	Paraoxonase	584G→A
Thrombomodulin	2136C→T	Plasminogen-activator inhibitor-1	-668/4G→5G
Thrombopoietin	5713A→G	Stromelysin-1	-1171/5A→6A
Thrombospondin 4	1186G→C	Tumor necrosis factor-α	-850C→T
Transforming growth factor-β1	869T→C	Tumor necrosis factor-α	-238G→A
Tumor necrosis factor-α	-863C→A		

Fig.6

	POBA (n = 910)		Stent implantation (n = 710)	
	No restenosis (n = 525)	Restenosis (n = 385)	No restenosis (n = 527)	Restenosis (n = 183)
Age (years)	58.5 ± 9.5	55.9 ± 9.6*1	56.8 ± 8.8	53.8 ± 9.9*2
Body mass index (kg/m <sup>2</sup> )	24.0 ± 2.9	24.2 ± 2.8	24.0 ± 3.0	23.5 ± 2.9
Smoking (%)	77.0	81.3	88.4	94.5‡
Hypertension (%)	68.0	79.5*2	77.8	83.1
Systolic BP (mmHg)	147.5 ± 25.3	152.6 ± 26.4*4	149.1 ± 25.9	156.4 ± 24.4*4
Diastolic BP (mmHg)	80.9 ± 14.0	85.4 ± 17.1*1	82.7 ± 15.2	87.0 ± 17.3*4
Diabetes mellitus (%)	32.4	40.0*3	41.4	50.3*3
Fasting blood sugar (g/dL)	119.5 ± 54.5	123.5 ± 47.8	118.6 ± 43.7	125.1 ± 54.2
Hypercholesterolemia (%)	57.3	56.9	56.9	55.2
Total cholesterol (mg/dL)	208.9 ± 43.0	210.9 ± 45.0	210.7 ± 48.1	203.0 ± 47.1
Triglycerides (mg/dL)	158.5 ± 101.9	147.0 ± 93.6	152.1 ± 129.9	139.0 ± 75.3
HDL-cholesterol (mg/dL)	46.4 ± 13.1	44.3 ± 13.6	44.4 ± 12.2	44.3 ± 14.1
Hyperuricemia (%)	23.0	18.4	14.4	22.4*3
Uric acid (mg/dL)	6.0 ± 1.6	5.8 ± 1.6	5.8 ± 1.7	5.6 ± 1.4
Coronary lesions				
Right coronary artery (%)	30.5	28.3	32.4	39.9
Left anterior descending (%)	45.1	48.6	52.8	45.4
Left circumflex (%)	24.4	23.1	14.8	14.8

Fig.7

	POBA (n = 480)		Stent implantation (n = 291)	
	No restenosis (n = 286)	Restenosis (n = 194)	No restenosis (n = 204)	Restenosis (n = 87)
Age (years)	63.1 ± 10.2	65.8 ± 7.7*1	63.2 ± 8.8	67.0 ± 9.8*1
Body mass index (kg/m <sup>2</sup> )	23.7 ± 3.4	23.4 ± 3.1	23.9 ± 3.3	23.5 ± 2.6
Smoking (%)	15.4	24.7*2	32.4	20.7*2
Hypertension (%)	65.0	62.9	85.3	55.2*3
Systolic BP (mmHg)	149.4 ± 28.3	148.2 ± 27.5	148.4 ± 31.0	156.1 ± 28.7
Diastolic BP (mmHg)	79.0 ± 15.5	77.8 ± 15.6	78.9 ± 14.0	84.5 ± 14.6*2
Diabetes mellitus (%)	32.2	45.4*1	42.6	79.3*3
Fasting blood sugar (g/dL)	121.6 ± 53.4	141.3 ± 65.4*1	135.9 ± 72.0	152.3 ± 57.0*4
Hypercholesterolemia (%)	69.9	63.9	70.6	72.4
Total cholesterol (mg/dL)	211.7 ± 38.4	213.1 ± 44.5	219.1 ± 46.6	218.7 ± 40.2
Triglycerides (mg/dL)	127.8 ± 61.8	129.6 ± 73.0	134.2 ± 82.7	161.0 ± 119.2*2
HDL-cholesterol (mg/dL)	47.4 ± 13.4	46.8 ± 14.6	56.2 ± 17.4	54.4 ± 13.5
Hyperuricemia (%)	17.5	22.7	33.8	17.2*1
Uric acid (mg/dL)	4.6 ± 1.2	4.6 ± 1.5	4.9 ± 1.4	4.8 ± 1.3
Coronary arteries				
Right coronary (%)	22.7	47.9*3	45.6	34.5
Left anterior descending (%)	41.6	41.8	39.7	55.2*2
Left circumflex (%)	35.7	10.3‡	14.7	10.3

Fig.8

Gene	SNP	Dominant		Recessive		Additive	
		P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)
<b>POBA</b>							
Glycoprotein Ia	1684A→G	0.7410		<b>0.0012</b>	0.5 (0.3-0.8)	0.7401	
G-protein β3 subunit	825C→T	0.2916		<b>0.0033</b>	1.6 (1.2-2.3)	0.0119	1.6 (1.1-2.4)
Tumor necrosis factor-α	-863C→A	<b>0.0066</b>	1.5 (1.1-2.1)	0.8408		0.0039	1.6 (1.2-2.3)
Apolipoprotein C-III	-482C→T	<b>0.0096</b>	1.5 (1.1-2.1)	0.1986		0.0216	1.6 (1.1-2.4)
Apolipoprotein E	3932T→C	<b>0.0101</b>	1.6 (1.1-2.4)	0.7705		0.0103	1.7 (1.1-2.5)
Angiotensinogen	-6G→A	<b>0.0307</b>	0.4 (0.2-0.9)	0.4615		0.0306	0.4 (0.17-0.90)
<b>Stent implantation</b>							
Tumor necrosis factor-α	-863C→A	0.0415	1.5 (1.0-2.1)	<b>0.0142</b>	2.0 (1.1-3.6)	0.0082	2.2 (1.2-3.9)
Thrombomodulin	2136C→T	<b>0.0143</b>	1.6 (1.1-2.3)	0.2937		0.0241	1.6 (1.1-2.3)
Thrombospondin 4	1186G→C	<b>0.0229</b>	1.7 (1.1-2.7)			0.0229	1.7 (1.1-2.7)
Platelet-activating factor acetylhydrolase	994G→T	<b>0.0475</b>	1.5 (1.0-2.2)	0.3905		0.0666	
Thrombopoietin	5713A→G	0.3159		<b>0.0499</b>	1.5 (1.0-2.1)	0.8858	

Fig.9

Gene	SNP	Dominant		Recessive		Additive	
		P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)
<b>POBA</b>							
Fatty acid-binding protein 2	2445G→A	<b>0.0001</b>	2.3 (1.5-3.6)	0.0014	2.7 (1.5-4.9)	0.0001	3.8 (2.0-7.4)
Plasminogen-activator inhibitor-1	-668/4G→5G	<b>0.0091</b>	1.8 (1.2-2.7)	0.6798		0.0030	2.0 (1.3-3.1)
Glycoprotein Ib $\alpha$	1018C→T	<b>0.0117</b>	1.8 (1.1-2.8)	0.7326		0.0003	2.4 (1.5-3.9)
Paraoxonase	584G→A	<b>0.0174</b>	1.6 (1.1-2.4)	0.0270	2.4 (1.1-5.1)	0.0098	2.8 (1.3-6.2)
E-selectin	561A→C	<b>0.0249</b>	2.9 (1.2-7.7)			0.0249	2.9 (1.2-7.7)
Apolipoprotein E	3932T→C	<b>0.0462</b>	1.7 (1.0-2.8)	0.5308		0.0691	
<b>Stent implantation</b>							
Plasminogen-activator inhibitor-1	-668/4G→5G	<b>0.0013</b>	3.2 (1.6-6.5)	0.6063		0.0003	4.2 (2.0-9.3)
Paraoxonase	584G→A	<b>0.0083</b>	2.5 (1.3-4.9)	0.4102		0.0114	2.5 (1.2-5.0)
Glycoprotein Ib $\alpha$	1018C→T	<b>0.0187</b>	2.6 (1.2-5.7)			0.0187	2.6 (1.2-5.7)
Apolipoprotein E	3932T→C	<b>0.0299</b>	2.5 (1.1-5.9)	0.8671		0.0046	3.6 (1.5-8.7)
Apolipoprotein C-III	-482C→T	0.0602		<b>0.0337</b>	2.3 (1.1-5.0)	0.7313	

**Fig.10**

Gene	chromosomal locus	SNP	Genetic model	P	Odds ratio	95% CI
POBA						
Apolipoprotein E	19q13.2	3932T→C	CC + TC versus TT	0.0035	1.80	1.21-2.66
Glycoprotein Ia	5q23-q31	1684A→G	GG versus AG + AA	0.0162	0.57	0.37-0.90
Tumor necrosis factor- $\alpha$	6p21.3	-863C→A	AA + CA versus CC	0.0075	1.54	1.12-2.11
G-protein $\beta 3$ subunit	12p13	825C→T	TT versus CT + CC	0.0187	1.51	1.07-2.12
Apolipoprotein C-III	11q23	-482C→T	TT + CT versus CC	0.0236	1.44	1.05-1.98
Angiotensinogen	1q42-q43	-6G→A	AA + GA versus GG	0.4384	0.70	0.29-1.70
Stent implantation						
Thrombospondin 4	5q13	1186G→C	CC + GC versus GG	0.0217	1.75	1.08-2.81
Tumor necrosis factor- $\alpha$	6p21.3	-863C→A	AA versus CA + CC	0.1140	1.61	0.89-2.91
Thrombomodulin	20p11.2	2136C→T	TT + CT versus CC	0.0767	1.42	0.96-2.08
Thrombopoietin	3q26.3-q27	5713A→G	GG versus AG + AA	0.1266	1.36	0.92-2.02
Platelet-activating factor acetylhydrolase	6p21.2-p12	994G→T	TT + GT versus GG	0.3460	1.22	0.81-1.84

Fig.11

Gene	chromosomal locus	SNP	Genetic model	P	Odds ratio	95% CI
POBA						
E-selectin	1q23-q25	561A→C	CC + AC versus AA	0.0227	3.54	1.19-10.52
Fatty acid-binding protein 2	4q28-q31	2445G→A	AA + GA versus GG	0.0002	2.42	1.52-3.85
Glycoprotein Ib $\alpha$	22q11.2	1018C→T	TT + CT versus CC	0.0111	1.86	1.15-3.02
Plasminogen activator inhibitor-1	7q21.3-q22	-668/4G→5G	5G/5G + 4G/5G versus 4G/4G	0.0475	1.62	1.01-2.60
Paraoxonase	7q21.3	584G→A	AA + GA versus GG	0.0994	1.45	0.93-2.25
Apolipoprotein E	19q13.2	3932T→C	CC + TC versus TT	0.5569	1.19	0.661-2.16
Stent implantation						
Plasminogen activator inhibitor-1	7q21.3-q22	-668/4G→5G	5G/5G + 4G/5G versus 4G/4G	0.0006	3.88	1.78-8.45
Apolipoprotein C-III	11q23	-482C→T	TT versus CT + CC	0.0100	3.11	1.31-7.38
Paraoxonase	7q21.3	584G→A	AA + GA versus GG	0.0116	2.67	1.24-5.72
Glycoprotein Ib $\alpha$	22q11.2	1018C→T	TT + CT versus CC	0.0754	2.23	0.92-5.42
Apolipoprotein E	19q13.2	3932T→C	CC + TC versus TT	0.3174	1.64	0.62-4.35

10/524021

Fig.12

Apolipoprotein E (0 = TT, 1 = CC)	Glycoprotein Ia (0 = AA + AG, 1 = GG)	Tumor necrosis factor- $\alpha$ (0 = CC, 1 = CA = AA)	G-protein $\beta\gamma$ subunit (0 = CC = CT, 1 = TT)	Apolipoprotein C-III (0 = CC, 1 = CT = TT)	Odds ratio
1	0	1	1	1	10.55
1	0	1	1	0	7.33
1	0	1	0	1	6.99
1	0	1	0	0	4.85
1	0	0	1	1	6.85
1	0	0	1	0	4.76
1	0	0	0	1	4.54
1	0	0	0	0	3.15
1	1	1	1	1	6.03
1	1	1	1	0	4.19
1	1	1	0	1	3.99
1	1	1	0	0	2.77
1	1	1	1	1	3.91
1	1	1	1	0	2.72
1	1	1	0	1	2.59
1	1	1	0	0	1.80
0	0	0	1	1	5.86
0	0	0	1	0	4.07
0	0	0	0	1	3.88
0	0	0	0	0	2.70
0	0	0	1	1	3.81
0	0	0	1	0	2.64
0	0	0	0	1	2.52
0	0	0	0	0	1.75
0	0	0	1	1	3.35
0	0	1	1	1	2.33
0	0	1	0	0	2.22
0	0	1	1	1	1.54
0	0	1	1	1	2.17
0	1	1	0	1	1.51
1	1	0	0	0	1.44
1	1	0	0	1	1.00

Fig.13

Thrombospondin 4 (0 = GG, 1 = GC = CC)	Tumor necrosis factor- $\alpha$ (0 = CC + CA, 1 = AA)	Thrombomodulin (0 = CC, 1 = CT = TT)	Thrombopoietin (0 = AA = AG, 1 = GG)	Platelet-activating factor acetylhydrolase (0 = GG, 1 = GT = TT)	Odds ratio
1	1	1	1	1	6.64
1	1	1	1	0	5.44
1	1	1	0	1	4.88
1	1	1	0	0	4.00
1	1	0	1	1	4.67
1	1	0	1	0	3.83
1	1	1	1	0	3.44
1	1	1	0	1	3.44
1	1	0	0	0	2.82
1	1	1	1	1	4.12
1	0	1	1	0	3.38
1	0	1	0	1	3.03
1	1	1	0	0	2.49
1	1	0	0	1	2.90
1	1	0	1	1	2.38
1	1	0	0	0	2.14
1	1	0	0	0	1.75
1	0	1	1	1	3.79
1	1	1	1	1	3.11
1	1	1	0	0	2.67
1	0	0	0	1	2.79
0	0	1	1	0	2.29
0	0	1	0	1	2.19
0	0	0	0	1	1.96
0	0	0	0	0	1.61
0	0	0	1	1	2.36
0	0	0	1	0	1.93
0	0	0	1	1	1.73
0	0	0	1	1	1.42
0	0	0	0	0	1.66
0	0	0	1	1	1.36
0	0	0	0	0	1.22
0	0	0	0	1	1.00
0	0	0	0	0	1.00

Fig.14

E-selectin (0 = AA, 1 = AC = CC)	Fatty acid-binding protein 2 (0 = GG, 1 = GA + AA)	Glycoprotein Ib $\alpha$ (0 = CC, 1 = CT = TT)	Plasminogen activator inhibitor-1 (0 = 4G/4G, 1 = 4G/5G = 5G/5G)	Paraoxonase (0 = GG, 1 = GA = AA)	Odds ratio
1	1	1	1	1	37.43
1	1	1	1	0	25.81
1	1	1	0	1	23.10
1	1	1	0	0	15.93
1	1	0	1	1	20.12
1	1	0	1	0	13.88
1	1	0	0	0	12.42
1	1	0	0	0	8.57
1	0	1	1	1	15.47
1	0	0	1	0	10.67
1	1	1	1	0	9.55
1	1	1	0	0	6.58
1	1	0	1	1	8.32
1	1	0	1	0	5.74
1	1	0	0	0	5.13
1	1	0	0	0	3.54
0	1	1	1	1	10.57
0	0	1	1	0	7.29
0	0	1	0	1	6.53
0	0	1	0	0	4.50
0	0	0	1	1	5.69
0	0	0	1	0	3.92
0	0	0	0	1	3.51
0	0	0	0	0	2.42
0	0	0	1	1	4.37
0	0	0	1	0	3.01
0	0	0	0	1	2.70
0	0	0	0	0	1.86
0	0	0	1	1	2.35
0	0	0	1	0	1.62
0	0	0	0	1	1.45
0	0	0	0	0	1.00

**Fig.15**

Plasminogen activator inhibitor-1 (0 = 4G/4G, 1 = 4G/5G = 5G/5G)	Apolipoprotein C-III (0 = CC + CT, 1 = TT)	Paraoxonase (0 = GG, 1 = GA = AA)	Glycoprotein Ib $\alpha$ (0 = CC, 1 = CT = TT)	Apolipoprotein E (0 = TT, 1 = TC = CC)	Odds ratio
1	1	1	1	1	117.83
1	1	1	1	0	71.85
1	1	1	0	1	52.84
1	1	1	0	0	32.22
1	1	1	1	1	44.13
1	1	1	1	0	26.91
1	1	0	0	0	19.79
1	1	1	0	1	12.07
1	1	0	0	0	37.89
1	0	1	1	1	23.10
1	0	1	1	0	16.99
1	0	0	0	0	10.36
1	0	0	0	1	14.19
1	0	0	1	1	8.65
1	0	0	0	0	6.36
1	0	0	0	0	3.88
0	1	1	1	1	30.37
0	0	1	1	0	18.52
0	0	1	0	1	13.62
0	0	1	0	0	8.30
0	0	1	1	1	11.37
0	0	1	1	0	6.94
0	0	1	0	1	5.10
0	0	1	0	0	3.11
0	0	0	0	0	9.76
0	0	0	0	0	5.95
0	0	0	1	0	4.38
0	0	0	0	1	2.67
0	0	0	0	1	3.66
0	0	0	1	0	2.23
0	0	0	0	0	1.64
0	0	0	0	0	1.00

**Fig.16**